Researchers have announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for D-PLEX100, a new treatment aimed at preventing surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery. This acceptance comes with a Priority Review designation, which accelerates the FDA’s review timeline from ten months to approximately six months. The target action date for the FDA’s decision is set for November 28, 2026, which is earlier than previously expected.

This development is significant for anyone facing abdominal surgery, as SSIs can lead to serious complications and extended recovery times. D-PLEX100 aims to provide local, controlled release of the antibiotic doxycycline directly at the surgical site for up to 30 days, potentially reducing the risk of infections, including those caused by antibiotic-resistant bacteria. In clinical trials, D-PLEX100 demonstrated a 60% reduction in SSI incidence compared to standard care, highlighting its potential effectiveness in improving surgical outcomes.

The FDA’s acceptance of the NDA is based on strong evidence from the Phase 3 SHIELD II trial, which showed promising results for D-PLEX100. However, while the findings are encouraging, the treatment has not yet been approved for use. The company, PolyPid, is committed to supporting the FDA’s review process and aims for a commercial launch in early 2027 if the drug receives approval.

For those preparing for surgery, it may be worthwhile to discuss with your healthcare provider the potential benefits of new treatments like D-PLEX100, especially if you are concerned about the risk of infections.

Source